Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.

This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.

Barchart

Why isn’t Ozempic on Australia’s Pharmaceutical Benefits Scheme for weight loss? And should it be?

The drug is subsidised for treatment of type 2 diabetes but experts say it could help reduce other health problems associated with severe obesity

The Guardian - AU

Wegovy maker Novo Nordisk rebuked by watchdog over failure to disclose payments to UK health groups

Danish drug giant found to have failed to accurately report spending even after admitting to errors

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

‘Skinny jabs’ are turning slimmers teetotal – and drinks companies are feeling the loss

As the public rejoice at shedding weight, the likes of Wegovy seem to be controlling other bad habits – in particular drinking to excess

The Guardian - UK

Novo Nordisk stock surges 7% on new weight-loss drug update

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Fortune

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

Kiplinger

Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.

Investors Business Daily

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

MarketBeat

LVMH dethrones Novo Nordisk as Europe's most valuable company

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Fortune

Novo Nordisk CEO attends crisis talks with Danish PM amid Trump's Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats over Greenland.

Fortune

Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts

Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.

Investors Business Daily

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

The Conversation

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

FDA Approves Generic Version Of Diabetes Drug Liraglutide

FDA approves generic liraglutide for type 2 diabetes, offering affordability and addressing shortage.

Investors Business Daily

Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review

The stock market tumbled this week on the less-dovish Fed rate-cut outlook, with Treasury yields hitting five-month highs.

Fortune

Novo Nordisk faces stock market bloodbath after drug trial disappoints

Shares in Novo Nordisk plunged 20% on Friday.

Investors Business Daily

Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

International Business Times

Ozempic May Face Investigation Over Vision-Threatening Condition In Some Patients

Danish health authorities asked the European Union to review two studies linking Novo Nordisk's diabetes drug, Ozempic, to a rare eye condition.

MarketBeat

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.